Journal of Nuclear Science, Engineering and Technology (JONSAT)
In cooperation with the Iranian Nuclear Society

Determination of optimized conditions for 99mTc-labeled riphampicin Preparation for tuberculosis imaging applications

Document Type : Research Paper

Authors

Ali Badbarin
Amirreza jalilian
Fariba Jouhari Deha
Hassan Yousefnia
Mitra Atharialaf
Abstract
Developing of new infection imaging agents is a mandate in the detection of resistant species in the clinic due to the mortality of various new strains of bacteria including mycobacterium tuberculosis. In this study, various conditions were optimized for the rapid and efficient labeling of rifampicin antibiotic labeled with Tc-99m for ultimate use in infection imaging. Radiochemical purities were checked by RTLC using methyl ethyl ketone, and normal saline on Whatman No.1 paper. The time, temperature, ligand concentration, stannous ion amount, pH were optimized in the radiolabeling process and the best conditions were room temperature, pH 7, 20 micrograms of stannous chloride for 1 mg of rifampicin solid and 20 mCi of freshly milked technetium-99m pertechnetate. The complex demonstrated satisfactory stability in the presence of human serum and final formulations for 6 hours.
 

Keywords

Rifampicin
Technetium-99 m
Radiolabeling
Tuberculosis
[1] F.A. Drobniewski, S.M. Wilson, The pathological society of great britain and ireland, review article the rapid diagnosis of isoniazid and rifampicin resistance in mycobacterium tuberculosis- a molecular story- Med, Microbiol, 47 (1998) 189-1960.
[2] J.M. Musser, Antimicrobial agent resistance in mycobacteria: molecular genetic insights, Clinical Microbiology Reviews, 8 (1995) 496-514.
[3] M.J. Nasiri, H. Dabiri, D. Darban-Sarokhalil, M. Rezadehbashi, S. Zamani, Prevalence of drug-resistant tuberculosis in Iran: systematic review and meta-analysis, Am J Infect Control, 42 (2014) 1212-1218.
[4] http://www.naweb.iaea.org/ napc/iachem/ meetings/ meetings_tm.html TM-44702 on, Infection imaging with radiopharmaceuticals, (joint with NAHU) 2013-03-18 to 2013-03-22 U. Bhonsle/ A. Duatti, Vienna Austria.
[5] G. Tossing, 99mTc-ciprofloxacin draximage. Review IDrugs, 7(4) (2004) 374-379.
[6] Technetium [99mTc] ciprofluxacin, Injection, Powder, Lyophilized, Iranian Drug List, fdo. behdasht. gov.ir/ index.aspx? siteid=114 & pageid=29768.
[7] A.R. Jalilian, Y. Yari-Kamrani, P. Rowshanfarzad, M. Sabet, M. Kamali-dehghan, Preparation and preliminary evaluation of [55Co] (II) vancomycin, Journal of Nuclear Science and Technique, 19 (6) (2008) 347-353.
[8] A.R. Jalilian, M.A. Hosseini, F. Saddadi, Evaluation of [201Tl] (III) vancomycin in normal rats, Nuclear Medicine Reviews, 11 (1) (2008) 1-4.
[9] http://icnm2013.com/ files/ basic %20 science %20 program.pd.
[10] P. Richards, Technetium-99m: The early days. BNL-43197 CONF-8909193-1 (1989). New York: Brookhaven National Laboratory, Retrieved, 3 (2012).
[11] P.P. Hazari, K. Chuttani, N. Kumar, R. Mathur, R. Sharma, B. Singh, A.K. Mishra, Synthesis and Biological Evaluation of Isonicotinic Acid Hydrazide Conjugated with Diethyelene triamine penta-acetic Acid for Infection Imaging, The Open Nuclear Medicine Journal, 1 (2009) 33-42.
[12] N. Singh, M. Gulati, M. Bose, A. Bhatnagar, A.K. Singh, T. Ravindranath, In-Vitro & In-Vivo Experiments on Selective Uptake of 99mTc-INH & 99mTc-EMB in Resistant Strains of Mycobacteria (Abstracts of SNMICON 2004), Indian Journal of Nuclear Medicine, 19 (2004) 156.
[13] M.T. Ercan, T. Aras, I.S. Unsal, Evaluation of 99mTc-erythromycin and 99mTc-streptomycin sulphate for the visualization of inflammatory lesions, Int. J. Rad. Appl. Instrum. B, 19(7) (1992) 803-806.
[14] S.Q. Shah, A. Ullah Khan, M.R. Khan, Radiosynthesis and biodistribution of 99mTc-rifampicin: A novel radiotracer for in-vivo infection imaging, Applied Radiation and Isotopes, 68 (2010) 2255–2260.
[15] S.W. Husain, V. Ghoulipour, H. Sepehrian, Chromatographic behaviour of antibiotics on thin layers of an inorganic ion-exchanger, Acta Chromatographica, 14 (2004) 102-109.

Home